Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau”

The first-line therapy of metastatic renal cell carcinoma (mRCC) has revolutionized with the approval of immune checkpoint inhibitors (ICIs) in combination with or without tyrosine kinase inhibitors (TKIs). The choice among the many different immuno-combinations (ICI-ICI or ICI-TKI) is challenging d...

Full description

Bibliographic Details

Published in:	Human Vaccines & Immunotherapeutics
Main Authors:	Sara Elena Rebuzzi, Giuseppe Fornarini, Alessio Signori, Pasquale Rescigno, Giuseppe Luigi Banna, Sebastiano Buti
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Subjects:	Renal cell carcinoma immune checkpoint inhibitor immuno-combination immunotherapy survival outcomes
Online Access:	https://www.tandfonline.com/doi/10.1080/21645515.2024.2351669